These are the STI-fighting super-condoms you don’t need

VivaGel condoms promise protection from viruses. But do they really work?

Condoms are an imperfect tool. They slip. They break. They leak. In a laboratory setting, condoms are a practically perfect impenetrable barrier against viruses, but in the real world, they struggle to be invincible; condoms have an 80-85 percent reduction rate for HIV infection, and are even less effective against HPV and herpes. Wouldn’t it be great if we had a next-generation condom that not only provided a barrier against infection, but also actively destroyed viruses in semen, mucus or vaginal fluid?

Well now we do. Maybe.

On Sept 13, 2016, pharmaceutical company Starpharma announced that it has secured Health Canada approval for condoms imbued with VivaGel, a drug it says deactivates nearly all HIV, HPV and herpes viruses in the lab.

The condoms, marketed as LifeStyles Dual Protect, will hit shelves in Canada in 2017. The size of the asterisk hovering over the company’s health claims, however, should give pause to anyone hoping for a bulletproof defense against sexually transmitted infections (STIs).

Starpharma’s condoms are coated with an antimicrobial gel full of large organic polymer molecules called astodrimer, which bond to the outside of bacteria and viruses and deactivate them (since viruses aren’t precisely alive, “kill” isn’t quite the right word). In a petri dish, studies show the gel knocks out 99.9 percent of HIV, HPV and herpes virus. Starpharma has also dosed semen and vaginal fluid with the drug, and shown a similar reduction in viral load.

Scroll to Top

During the Canada Post strike announced September 25, 2025, the following measures will be undertaken to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory has transitioned to private courier for delivery of outgoing reports and documents. Results required urgently can be faxed upon request. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy has transitioned to private courier for delivery of medications. We recommend requesting medication at least 2 weeks in advance in case of delivery delays, particularly to rural/remote parts of BC. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

During the Canada Post strike, we recommend that documents be faxed or couriered to our sites, versus utilization of regular mail service

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below